Trigenesis Biosciences Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 16-07-2024
- Paid Up Capital ₹ 5.00 M
as on 16-07-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -99.07%
(FY 2022)
- Profit -199.22%
(FY 2022)
- Ebitda 93.28%
(FY 2022)
- Net Worth -5.40%
(FY 2022)
- Total Assets -91.03%
(FY 2022)
About Trigenesis Biosciences
The Corporate was formerly known as Rsm Kilitch Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Vijay Nahar, Bhawarlal, and Sohanlal Maheshkumar serve as directors at the Company.
- CIN/LLPIN
U51900KA2011PTC056703
- Company No.
056703
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Trigenesis Biosciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Nahar  | Director | 19-Jan-2011 | Current |
| Bhawarlal | Director | 01-Jan-2019 | Current |
| Sohanlal Maheshkumar | Director | 01-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Trigenesis Biosciences.
Trigenesis Biosciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 99.07% decrease. The company also saw a substantial fall in profitability, with a 199.22% decrease in profit. The company's net worth dipped by a decrease of 5.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trigenesis Biosciences?
In 2022, Trigenesis Biosciences had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trigenesis Lifesciences Private LimitedActive 20 years 5 monthsVijay Nahar and Bhawarlal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Trigenesis Biosciences?
Trigenesis Biosciences has a workforce of 36 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trigenesis Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trigenesis Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
